Trials / Unknown
UnknownNCT04158011
A Retrospective Study of Patients With Leukemia Relapse in the CNS Treated With CAR T Cells
CARs for CNS-Leukemia Relapse: A Retrospective International Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (estimated)
- Sponsor
- Sheba Medical Center · Other Government
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
CAR T cells targeting CD19 have been approved for patients with relapsed or refractory ALL, failing two or more prior protocols. Several institutional-based studies with other CAR T cells targeting CD19 have demonstrated outstanding response rates in patients with refractory disease, and the ability of CAR T cells to clear CNS leukemia. Nevertheless, these cases are sparse and have never been reported collectively. Here, we aim to retrospectively assess toxicity and long term outcome of patients treated with CAR T cells for CNS relapse of ALL.
Conditions
Timeline
- Start date
- 2019-11-06
- Primary completion
- 2020-03-01
- Completion
- 2021-01-01
- First posted
- 2019-11-08
- Last updated
- 2019-11-08
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT04158011. Inclusion in this directory is not an endorsement.